Literature DB >> 30262325

Survival outcome of adjuvant radiotherapy after local excision for T2 early rectal cancer: An analysis based on the surveillance, epidemiology, and end result registry database.

Xiao-Jie Wang1, Pan Chi2, Yue-Yi Zhang1, Hui-Ming Lin1, Xing-Rong Lu1, Ying Huang1, Zong-Bin Xu1, Waleed M Ghareeb3, Sheng-Hui Huang1, Yan-Wu Sun1, Dao-Xiong Ye1.   

Abstract

BACKGROUND: Major resection (MR) is recommended for cases with T2 finding after local excision (LE) of early rectal cancer, but the revision procedure is accompanied with high morbidity. We evaluated the oncological safety of LE followed by adjuvant radiotherapy as a rectum-preserving alternative to MR for T2 early rectal cancer.
METHODS: A total of 3786 patients with T2N0M0 rectal adenocarcinoma between 1998 and 2013 were included from the SEER database. Survival rates were compared using the Kaplan-Meier method with a log-rank test, and multivariate analyses were performed using Cox proportional regression models.
RESULTS: Of these patients included, 429 (11.3%) treated with LE alone (LE group), 3067 (81.0%) treated with MR (MR group), and 290 (7.7%) treated with LE followed by adjuvant radiotherapy (LE + adjuvant RT group). The 5-year cancer specific survival (CSS) rate and 5-year overall survival (OS) rate were significantly lower in LE patients group than those in MR patients group (70.5% vs. 81.8%, P < 0.001; 57.3% vs. 72.3%, P < 0.001). The 5-year CSS rate and 5-year OS rate were similar between LE + adjuvant RT and MR groups (78.4% vs. 81.8%, P = 0.975, and 70.7% vs. 72.3%, P = 0.311, respectively). Multivariate Cox regression revealed that treatment strategies, age and CEA status were independently associated with CSS and OS. After age adjustment, LE was associated with reduced CSS (using MR as a reference, HR, 1.784; P < 0.001) and reduced OS (HR, 1.739; P < 0.001). However, CSS and OS related to LE + adjuvant RT of T2 rectal cancer group weren't be affected (HR, 0.994; P = 0.962 and HR, 0.904; P = 0.302, respectively).
CONCLUSIONS: When MR is inappropriate for T2 early rectal cancer patients because of patients refusal or co-morbidities, LE + adjuvant RT can provide acceptable levels of long-term survival.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Adjuvant radiotherapy; Local excision; Rectal cancer; Survival

Mesh:

Year:  2018        PMID: 30262325     DOI: 10.1016/j.ejso.2018.08.024

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

1.  Comparison of Short-Term Clinical and Pathological Outcomes after Transanal versus Laparoscopic Total Mesorectal Excision for Low Anterior Rectal Resection Due to Rectal Cancer: A Systematic Review with Meta-Analysis.

Authors:  Mateusz Rubinkiewicz; Agata Czerwińska; Piotr Zarzycki; Piotr Małczak; Michał Nowakowski; Piotr Major; Andrzej Budzyński; Michał Pędziwiatr
Journal:  J Clin Med       Date:  2018-11-19       Impact factor: 4.241

2.  Oncologic Nomogram for Stage I Rectal Cancer to Assist Patient Selection for Adjuvant (Chemo)Radiotherapy Following Local Excision.

Authors:  Shutao Zhao; Xin Chen; Dacheng Wen; Chao Zhang; Xudong Wang
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

3.  Total Mesorectal Excision vs. Transanal Endoscopic Microsurgery Followed by Radiotherapy for T2N0M0 Distal Rectal Cancer: A Multicenter Randomized Trial.

Authors:  Junwei Tang; Yue Zhang; Dongsheng Zhang; Chuan Zhang; Kangpeng Jin; Dongjian Ji; Wen Peng; Yifei Feng; Yueming Sun
Journal:  Front Surg       Date:  2022-02-01

4.  Analysis of prognosis, genome, microbiome, and microbial metabolome in different sites of colorectal cancer.

Authors:  Yang Xi; Pan Yuefen; Wu Wei; Qi Quan; Zhuang Jing; Xu Jiamin; Han Shuwen
Journal:  J Transl Med       Date:  2019-10-29       Impact factor: 5.531

5.  Adequate Lymph Node Assessments and Investigation of Gut Microorganisms and Microbial Metabolites in Colorectal Cancer.

Authors:  Shuwen Han; Wei Wu; Miao Da; Jiamin Xu; Jing Zhuang; Longqi Zhang; Xiaoxiang Zhang; Xi Yang
Journal:  Onco Targets Ther       Date:  2020-03-04       Impact factor: 4.147

6.  Oncological outcome after local treatment for early stage rectal cancer.

Authors:  Caroline D M Witjes; Abhilashaben S Patel; Aniruddh Shenoy; Stephen Boyce; James E East; Christopher Cunningham
Journal:  Surg Endosc       Date:  2021-02-05       Impact factor: 4.584

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.